ReviewExpert opinion on investigational drugs2015
Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.
Review in Expert opinion on investigational drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Alzheimer's Disease: From Pathogenesis to Emerging Therapeutic Targets.Journal of clinical medicine · 2026Review
- Genetic background of cognitive decline in Parkinson's disease.Frontiers in cognition · 2024Review
- Review
- Recent Trends in Active and Passive Immunotherapies of Alzheimer's Disease.Antibodies (Basel, Switzerland) · 2023Review
- Article
- Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives.Frontiers in neuroscience · 2022Review
- Cholinesterase inhibitors as Alzheimer's therapeutics (Review).Molecular medicine reports · 2019Review
- Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings.Journal of Alzheimer's disease reports · 2019Review
- Characterization of 3 Novel Tau Radiopharmaceuticals,Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- The Role of Mitochondrial Dysfunction in the Progression of Alzheimer's Disease.Current medicinal chemistry · 2018Review
- Tau passive immunization inhibits not only tau but also Aβ pathology.Alzheimer's research & therapy · 2017Article
- The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.Acta neuropathologica communications · 2016Article
- Pyrrolo[2,3-c]pyridines as Imaging Agents for Neurofibrilary Tangles.ACS medicinal chemistry letters · 2016Article
- Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.BioMed research international · 2016Review
- Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged.Frontiers in immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionAlzheimer's disease (AD) is a progressive neurodegenerative disorder that is a significant burden to society. With continual expansion of our understanding of the disease, novel therapies are emerging as potential therapeutics to either halt or reverse progression of the disease. AREAS COVERED: This paper aims to provide an overview of current drug therapies aimed at targeting the tau protein. With this protein known to be a noted pathologic finding of the disease, trials of therapeutics aimed at this protein have been under investigation. This article is based on data obtained from PubMed searches, TauRx, ALZFORUM, and Clinicaltrials.gov with search terms including: anti-tau, tau therapeutic agents in AD, Phase 0, I, II, III trials in AD, monoclonal antibodies and vaccines. EXPERT OPINION: Broad-based treatments that target tau, including microtubule stabilization and tau aggregation inhibitors, appear to be of greatest promise. Immunotherapy appears to be relatively safe and efficacious but narrow whereas protein kinase inhibition has not demonstrated clinical benefit to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.